Patients in the non-adherence group were with younger age (58.6 ± 15.6 years vs 62.2 ± 14.9 years, P < 0.001), less baseline CHD (38.5 vs 51.0%, P < 0.001), less baseline acute myocardial infarction (9.9 vs 20.4%, P < 0.001); lower NT-proBNP level (median, 3,506.5 pg/ml vs 4,198.0 pg/ml; P = 0.01); more prescriptions of ARB or CCB (37.2 vs 29.6%, P = 0.02; 25.7 vs 17.6%, P = 0.003), and less prescriptions of oral furosemide, venous furosemide, or aldosterone receptor antagonist (23.7 VS 32.9%, P = 0.003; 64.1 vs 71.1%, P = 0.03; 78.9 vs 86.5%, P = 0.002) than the adherence group. This evidence concerns the gene NR3C2 and coronary artery disorder.